E1A as a Tumor Suppressor Gene

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 2905-2907

  Frisch, Steven M ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS A1A PROTEIN; CTBP PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A LIPID COMPLEX; PROTEIN; PROTEIN P300; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER THERAPY; CLINICAL TRIAL; E1A GENE; GENE; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; HUMAN; ONCOGENE NEU; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; TUMOR SUPPRESSOR GENE; VIRAL GENE THERAPY;

ADENOVIRUS E1A PROTEINS; BYSTANDER EFFECT; CLINICAL TRIALS, PHASE I; FEMALE; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; INJECTIONS, INTRAPERITONEAL; LIPIDS; MULTICENTER STUDIES; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PLASMIDS; RECEPTOR, ERBB-2; RETINOBLASTOMA PROTEIN; TRANS-ACTIVATORS;

EID: 2442501467     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0644     Document Type: Review

References (39)

1. Zerler B, Moran B, Maruyama K, et al. Adenovirus E1A coding sequences that enable ras and pmt oncogenes to transform cultured primary cells. Mol Cell Biol 1986;6:887-99.
2. Byrd PJ, Grand RJ, Gallimore PH. Differential transformation of primary human embryo retinal cells by adenovirus E1 regions and combinations of E1A + ras. Oncogene 1988;2:477-84.
3. Gallimore PH, Grand RJ, Byrd PJ. Transformation of human embryo retinoblasts with simian virus 40, adenovirus and ras oncogenes. Anticancer Res 1986;6:499-508.
4. Seger YR, Garcia-Cao M, Piccinin S, et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002; 2:401-13.
5. Frisch SM. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc Natl Acad Sci USA 1991;88:9077-81.
6. Yu DH, Scorsone K, Hung MC. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol 1991;11:1745-50.
7. Yu D, Shi D, Scanlon M, Hung MC. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. Cancer Res 1993;53:5784-90.
8. Frisch SM, Dolter KE. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. Cancer Res 1995;55: 5551-5.
9. Dickopp A, Esche H, Swart G, et al. Transformation-defective adenovirus 5 E1A mutants exhibit antioncogenic properties in human BLM melanoma cells. Cancer Gene Ther 2000;7:1043-50.
10. Deng J, Xia W, Hung MC. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene 1998;17:2167-75.
11. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003;22:6570-8.
12. Montagna C, Andrechek ER, Padilla-Nash H, Muller WJ, Ried T. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene 2002;21: 890-8.
13. Chen H, Hung MC. Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene. J Biol Chem 1997;272: 6101-4.
14. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553-77.
15. Arany Z, Huang LE, Eckner R, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 1996;93: 12969-73.
16. 2-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression. Cancer Res 2002;62:346-50.
17. Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 1993;7:535-45.
18. cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature (Lond) 2002;419:729-34.
19. Somasundaram K, El-Deiry WS. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 1997;14:1047-57.
20. Jin Y, Zeng SX, Dai MS, Yang XJ, Lu H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem 2002;277:30838-43.
21. Doman D, Shimizu H, Perkins ND, Hupp TR. DNA-dependent acetylation of p53 by the transcription coactivator p300. J Biol Chem 2003;278:13431-41.
22. ARF tumor suppressor. Genes Dev 1998;12:2434-42.
23. Bell LA, Ryan KM. Life and death decisions by E2F-1. Cell Death Differ 2004;11:137-42.
24. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002;4:859-64.
25. Frisch SM. E1a induces the expression of epithelial characteristics. J Cell Biol 1994;127:1085-96.
26. Frisch SM. The epithelial cell default-phenotype hypothesis and its implications for cancer. Bioessays 1997;19:705-9.
27. Grooteclaes ML, Frisch SM. Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 2000;19:3823-8.
28. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neuoverexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 1997;15:953-60.
29. Zhou Z, Jia SF, Hung MC, Kleinerman ES. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res 2001;61:3394-8.
30. Cook JL, Miura TA, Ikle DN, Lewis AM Jr, Routes JM. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. Cancer Res 2003;63:3435-43.
31. Chinnadurai G. CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol Cell 2002;9:213-24.
32. Grooteclaes M, Deveraux Q, Hildebrand J, et al. C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs. Proc Natl Acad Sci USA 2003;100:4568-73.
33. Shao R, Xia W, Hung MC. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. Cancer Res 2000;60:3123-6.
34. Shao R, Hu MC, Zhou BP, et al. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities. J Biol Chem 1999;274:21495-8.
35. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a Phase I clinical trial. J Clin Oncol 2001;19:3422-33.
36. Hung MC, Hortobagyi GN, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biol 2000;465:171-80.
37. Ueno NT, Xia W, Tucker SD, et al. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncol Rep 1999;6:257-62.
38. Ueno NT, Yu D, Hung MC. E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer 2001;8:285-93.
39. Madhusudan S, Bates N, Flanagan E, et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004;10:2905-2907.